Anzeige
Mehr »
Lynx Broker
Login
Sonntag, 18.08.2019 Börsentäglich über 12.000 News von 605 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Zur alten Webversion

WKN: 677134 ISIN: SE0000789711 Ticker-Symbol: BIX 
Frankfurt
16.08.19
15:43 Uhr
0,090 Euro
-0,003
-2,69 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOINVENT INTERNATIONAL AB Chart 1 Jahr
5-Tage-Chart
BIOINVENT INTERNATIONAL AB 5-Tage-Chart

Aktuelle News zur BIOINVENT Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoUSPTO Intends to Grant BioInvent Patent Relating to BI-1206153LUND, Sweden , Aug. 15, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of...
► Artikel lesen
MiInvitation to Presentation of BioInvent's Interim Report Q2-2019 on August 22, 2019170LUND, Sweden, Aug. 14, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) will issue its interim report for the second quarter 2019 on Thursday August 22 at 8.30 a.m. CEST, followed...
► Artikel lesen
31.07.BioInvent Announces Selection of First Target Discovered by BioInvent's Proprietary F.I.R.S.TTM Technology Platform Under Collaboration With Pfizer Inc.25LUND, Sweden, July 31, 2019 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that Pfizer Inc. ("Pfizer") (NYSE: PFE) has selected the...
► Artikel lesen
Börsennews zur BIOINVENT Aktie und weiteren Hot Stocks erhalten
04.07.BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application6LUND, Sweden, July 4, 2019 /PRNewswire/ -- BioInvent International AB (BINV) today announced it will receive a $0.5 million milestone payment related to the acceptance by the U.S. Food and...
► Artikel lesen
02.07.Bioinvent Receives Ind Approval For Phase I/iia Trial of Anti-fcyriib Antibody15LUND, Sweden, July 2, 2019 /PRNewswire/ -- BioInvent International AB (BINV) today announces it has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with an...
► Artikel lesen
12.06.BioInvent Publishes First Clinical Data From BI-1206 Phase l/lla Trials7LUND, Sweden, June 12, 2019 /PRNewswire/ -- BioInvent International AB (BINV) today announces the publication of the first data from two parallel Phase l/lla clinical trials of its lead product...
► Artikel lesen
03.06.BioInvent Submits IND for Phase I/IIa Trial of Anti-FcyRIIB Antibody8LUND, Sweden, June 3, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) today announces the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug...
► Artikel lesen
22.05.BioInvent International AB (publ) reports Q1 results1
22.05.BioInvent Interim Report January 1 - March 31, 20196LUND, Sweden, May 22, 2019 /PRNewswire/ -- Net sales SEK 17.4 (11.3) millionEarnings after tax SEK -27.8 (-24.9) million Earnings after tax per share before and after dilution: SEK -0.08 (-0.08)...
► Artikel lesen
26.04.BioInvent Receives €0.75 Million Milestone Under Mitsubishi Tanabe Pharma Partnership13LUND, Sweden, April 26, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) announced today that it has received a €0.75 million milestone payment under its collaboration with Mitsubishi...
► Artikel lesen
27.03.Transgene, BioInvent extend collaboration to develop multifunctional oncolytic viruses for treatment of solid tumors-
26.03.Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares in BioInvent International AB (41/19)43With effect from March 28, 2019, the subscription rights in BioInvent International AB will be quoted on the list for Equity rights. Quotation will continue up until April 10, 2019. Instrument: ...
► Artikel lesen
26.03.BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors7LUND, Sweden and STRASBOURG, France, March 26, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV), a biotech company focused on the discovery and development of novel immuno-regulatory...
► Artikel lesen
26.03.Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors10Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors and BioInvent...
► Artikel lesen
21.03.BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors2- Proprietary n-CoDeR & F.I.R.S.T. platforms yield wealth of candidates LUND, Sweden , March 21, 2019 /PRNewswire/ --BioInvent International AB (OMXS: BINV), focused on the discovery...
► Artikel lesen
21.03.XFRA CAPITAL ADJUSTMENT INFORMATION - 22.03.2019 - 127FOLGENDE WERTPAPIERE WERDEN AM 21.03.2019 CUM KAPITALMASSNAHME UND AM 22.03.2019 EX KAPITALMASSNAHME GEHANDELT. THE FOLLOWING SHARES ARE TRADED CUM CAPITAL ADJUSTMENT ON 21.03.2019 AND EX CAPITAL ADJUSTMENT...
► Artikel lesen
19.03.Notice to Annual General Meeting in BioInvent International AB6LUND, Sweden, March 19, 2019 /PRNewswire/ -- The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting (the "AGM")...
► Artikel lesen
13.03.BioInvent Expands U.S. Patent Protection for its F.I.R.S.T. Platform9LUND, March 13, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) announces today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance, informing...
► Artikel lesen
12.03.BioInvent Announces Publication of Review Article in Frontiers in Immunology on Resistance to Antibody Drugs4- Data demonstrate that the activating and inhibitory Fc gamma receptors control antitumor immunity LUND, Sweden, March 12, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV)...
► Artikel lesen
25.02.Bioinvent AB reports Q4 results3
Seite:  Weiter >>
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1